Dr. Eric Haura on New Biomarker Assay System for Lung Cancer

Eric Haura, MD
Published: Monday, May 11, 2015



Eric Haura, MD, senior member, Moffitt Cancer Center, discusses new approaches to identifying bypass signaling mechanisms and biomarkers in lung cancer.

Proteins encoded by genes don’t work in isolation, but they work as part of larger molecular machines, explained Haura. He and his colleagues have developed a biomarker assay system that can visualize and quantify those molecular machines. The technology is currently focused in lung cancer, but can be applied to many other tumor types.

The assay can visualize the acquisition of bypass signaling mechanisms that can cause tumors to escape targeted drugs.

This technology could be placed in diagnostic laboratories and eventually guide clinicians on how to make drug management decisions, says Haura.



Eric Haura, MD, senior member, Moffitt Cancer Center, discusses new approaches to identifying bypass signaling mechanisms and biomarkers in lung cancer.

Proteins encoded by genes don’t work in isolation, but they work as part of larger molecular machines, explained Haura. He and his colleagues have developed a biomarker assay system that can visualize and quantify those molecular machines. The technology is currently focused in lung cancer, but can be applied to many other tumor types.

The assay can visualize the acquisition of bypass signaling mechanisms that can cause tumors to escape targeted drugs.

This technology could be placed in diagnostic laboratories and eventually guide clinicians on how to make drug management decisions, says Haura.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x